12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lebrikizumab regulatory update

Roche disclosed in its 3Q12 earnings that it will delay submission of regulatory applications for asthma candidate lebrikizumab to after 2016. The pharma said...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >